BioMarin Pharmaceuticals
BMRN
551 hedge funds and large institutions have $15.6B invested in BioMarin Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 216 increasing their positions, 177 reducing their positions, and 50 closing their positions.
33% more call options, than puts
Call options by funds: $134M | Put options by funds: $101M
26% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 50
22% more repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 177
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
7% more capital invested
Capital invested by funds: $14.7B → $15.6B (+$969M)
3.71% more ownership
Funds ownership: 96.76% → 100.47% (+3.7%)
2% more funds holding
Funds holding: 542 → 551 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$361M |
| 2 |
Amundi
Paris,
France
|
+$129M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$87.9M |
| 4 |
Man Group
London,
United Kingdom
|
+$48.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$141M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$62.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$46.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$25.7M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$24.9M |
BMRN Hedge Fund Activity: Q3 2022 in Review
551 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2022, worth a combined $15.6B — up 6.6% from $14.7B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new BMRN positions and 50 closed out — a net gain of 13 holders — while 216 added to existing stakes and 177 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $361M. The largest seller was UBS Group, cutting an estimated $141M.
- 551 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2022, up from 542 in Q2 2022.
- Funds reported $15.6B of BioMarin Pharmaceuticals stock for Q3 2022, up 6.6% quarter-over-quarter.
- 63 funds opened new BioMarin Pharmaceuticals positions in Q3 2022 and 50 closed out, a net change of +13 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2022 was Janus Henderson Group, an estimated $361M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2022 was UBS Group, an estimated $141M sold.
Based on aggregated 13F filings for Q3 2022.